Bioventus Invests $15 Million in CartiHeal

CartiHeal Agili-C

Bioventus made an additional equity investment of $15 million in CartiHeal, developer of the Agili™-C implant for the treatment of joint surface lesions in traumatic and osteoarthritic joints. The investment follows the recently completed enrollment and outcome of interim analysis in CartilHeal’s multinational pivotal Investigational Device...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us